A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Sq
A phase 2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06668961 by Sichuan Baili Pharmaceutical Co., Ltd., with 48 participants enrolled, started 2024-11-07 and due to reach its primary completion in 2026-11. Interventions recorded: SI-B001, SI-B003. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
- TrialA Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
- TrialSI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer
Shares SI-B001, SystImmune / Sichuan Biokin.
- TrialA Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
- TrialA Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares SI-B001, SystImmune / Sichuan Biokin.
- TrialSI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
Shares SI-B001, SystImmune / Sichuan Biokin.
- TrialA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumor
Shares SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Shares SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.